Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia have?
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia has 29 citations in the OpenAlex counts ScholarIQ stores.
When was Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia published?
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia has 2019 year in the ScholarIQ index.
What is the open-access status of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia?
Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia has gold oa status in the ScholarIQ index.
What is the DOI of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia?
The DOI for Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia is on the source record.
What is the PMID of Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia?
The PMID for Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia is on the source record.
What is the OpenAlex record for Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia?
The OpenAlex for Genomic and epigenomic predictors of response to guadecitabine in relapsed/refractory acute myelogenous leukemia is on the source record.